ECOG-ACRIN EAY131

Primary Category:

Treatment Protocols

Disease Category:

Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma

Status:

Open

Molecular Analysis for Therapy Choice (MATCH)

Eligible for screening study DCP 001

NCT#02465060

The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites.  Approved genetic testing laboratories and their date of inclusion in the outside assay process are:

  • CARIS Life Sciences – 07/02/18
  • CellNetix Pathology and Laboratories – 02/13/19
  • Foundation Medicine – 07/02/18
  • GenPath BioReference Laboratories – 08/03/18
  • The Jackson Laboratory – 01/10/19
  • NeoGenomics Laboratories – 07/02/18
  • OmniSeq Laboratories – 07/16/18
  • PathGroup – 10/29/18
  • Quest Diagnostics Inc. – 05/20/19
  • Strata Oncology – 08/03/18
  • Tempus Laboratories – 07/16/18

The Biopsy consent form for this study is available upon request.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

(http://ecog-acrin.org/nci-match-eay131-designated-labs)